Multiple N-of-1 Trials of (Intermittent) Hypoxia Therapy in Parkinson's Disease
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
In recent years, mitochondrial dysfunction and oxidative stress have been implicated in PD
pathophysiology. Intermittent hypoxia therapy (IHT) is an upcoming treatment used by elite
athletes as well as fragile individuals in clinical settings that works by improving exercise
tolerance, neuroplasticity and inducing hypoxic preconditioning (HPC). HPC might improve the
oxidative stress response in PD on the long-term. In addition, preclinical evidence suggests
beneficial short-term effects such as influence on dopamine and noradrenalin release.
Anecdotal evidence indeed suggests that visiting high-altitude areas improves PD symptoms and
it is hypothesized that this effect results from decreased oxygen pressure at high altitudes.
The safety and feasibility of (intermittent) hypoxia therapy on PD symptoms will be assessed
in an exploratory phase I randomized-controlled trial.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Radboud University
Collaborator:
Michael J. Fox Foundation for Parkinson's Research